Mitotech CSO to Present Visomitin® Data in Dry Eye Disease and Glaucoma
February 24, 2022 02:00 ET
|
Mitotech S.A.
LUXEMBOURG, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, announced that its Chief Scientific Officer, Dr Maxim Skulachev, will give a full...
Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease
January 27, 2022 08:00 ET
|
Mitotech S.A.
Mitotech to be joined by John D. Sheppard, M.D., M.M.Sc. (Virginia Eye Consultants), Paul M. Karpecki, O.D., F.A.A.O. (Clinical Director of Advanced Ocular Surface Disease at Kentucky Eye Institute),...
Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON
December 16, 2021 02:00 ET
|
Mitotech S.A.
LUXEMBOURG, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company in ophthalmology, announced that the U.S. Food and Drug Administration (FDA) has...